February 21, 2008 14:03 ET

bioRASI to Showcase Its Translational Clinical Development Methodology at CTC 2008 in Orlando, FL

Global CRO Presents Its Unique Infrastructure to Optimize Innovative Therapeutics, Generics, and 505(b)(2) Programs

HOLLYWOOD, FL--(Marketwire - February 21, 2008) - bioRASI announced today its participation at the 2008 Clinical Trials Congress in Orlando, FL on February 25-27th. It will be exhibiting at booth #304 and will showcase its unique infrastructure that optimizes Innovative Therapeutics, Generics and 505(b)(2) Programs.

"bioRASI's Program Management Services Branch is a key component in developing innovative strategies and methodologies for optimizing the translational clinical development programs of our sponsors," said bioRASI's chairman, Dr. Boris Reznik. "At bioRASI, we leverage our in-depth scientific knowledge and regulatory specialists to uniquely design and implement successful trials for our sponsors, saving them critical amounts of time and money."

bioRASI's Program Management Services Branch uses an integrative management system infrastructure, known as BPI 2008, to successfully manage and optimize the outcome of the key translational steps, including discovery, IND enablement, and early clinical phase studies.

Through its Innovative and Generics divisions, bioRASI leverages its in-depth knowledge and global resources to provide a full range of services to its sponsors, including Program Management, Regulatory, Clinical, Data Management & Analysis, and Compliance & Audit.

"The clinical development process can be very convoluted with a high failure rate at phase II proof of concept," said Dr. Maguire, bioRASI Program Director. "We are able to help optimize our sponsor's clinical trials and reduce this high failure rate by leveraging our innovative application of scientific and clinical knowledge and our unique access to opinion leaders, principal investigators, clinics, special subject populations, regulatory venues, and other trial resources."

About bioRASI

bioRASI, the translational clinical development CRO, is focused on managing and optimizing the progression of lab candidates through clinical proof of efficacy and safety. bioRASI's Innovative Division helps companies bring their candidates from IND enablement through Phase II clinical proof studies and its Generics Division focuses on the translation of the candidate through pilot and pivotal clinical studies. bioRASI leverages its full service capabilities and global resources to achieve unparalleled scientific, clinical and business results for its sponsors. bioRASI is headquartered in Hollywood, FL and has regional offices, labs, and clinics in Eastern Europe and across the globe.

Contact Information